Sequential Myeloablative Autologous Stem Cell Transplantation and Reduced Intensity Allogeneic Stem Cell Transplantation in Children, Adolescents and Young Adults with Poor Risk Refractory or Recurrent Hodgkin (HL) and Non-Hodgkin Lymphoma (NHL)

Prakash Satwani(Pediatrics and Genetics), Mitchell S. Cairo(New York Medical College), James Garvin(Columbia University), Lauren Harrison(Gloucestershire Hospitals NHS Foundation Trust), Monica Bhatia(Columbia University Irving Medical Center), Zhezhen Jin, Jean Sosna(Columbia University), Joanne Kurtzberg(Duke University), Sonali Chaudhury(Northwestern University), Paul Martin(Duke Medical Center), Julie‐An Talano(Dana-Farber Cancer Institute), Margaret Peterson(Duke University), Diane George(Columbia University Irving Medical Center), Erin Morris(New York Medical College)
Transplantation and Cellular Therapy
February 1, 2014
10.1016/j.bbmt.2013.12.107
Cited by 1

Related Papers

Guidelines for the Management of Pediatric and Adult Tumor Lysis Syndrome: An Evidence-Based Review
|Journal of Clinical Oncology|2008|794
Hepatic Veno-Occlusive Disease following Stem Cell Transplantation: Incidence, Clinical Course, and Outcome
|Biology of Blood and Marrow Transplantation|2009|595
Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation
|Blood|2010|477
Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients
|Blood|2006|431
Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents
|Blood|2006|362